Hideaki Watanabe

Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b–infected null responders

Kazuaki Chayama, Shoichi Takahashi, Joji Toyota et al. · Hepatology · 2011 · 335 citations

Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options

Yoshiyuki Suzuki, Kenji Ikeda, Fumitaka Suzuki et al. · Journal of Hepatology · 2012 · 235 citations

Limited Treatment Options, Viral Hepatitis, Hcv Genotype 1B +9

Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir

Yoshiyasu Karino, Joji Toyota, Kenji Ikeda et al. · Journal of Hepatology · 2012 · 165 citations

Molecular Virology, Hepatitis C, Direct-acting Antivirals Daclatasvir +8

Asymmetric Catalysis on the Intramolecular Cyclopropanation of α-Diazo-β-keto Sulfones

Masahiro Honma, Takashi Sawada, Yuri Fujisawa et al. · Journal of the American Chemical Society · 2003 · 138 citations

Alpha-diazo-beta-keto Sulfones, Novel Organocatalysts, Engineering +11

Predictive Factors Associated With Acute Ocular Involvement in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis

Chie Sotozono, Mayumi Ueta, Eiji Nakatani et al. · American Journal of Ophthalmology · 2015 · 132 citations

Toxic Epidermal Necrolysis, Ocular Disease, Vitreous Body +8